High-efficacy targeting of colon-cancer liver metastasis with Salmonella typhimurium A1-R via intra-portal-vein injection in orthotopic nude-mouse models

Oncotarget. 2017 Mar 21;8(12):19065-19073. doi: 10.18632/oncotarget.12227.

Abstract

Liver metastasis is the main cause of colon cancer-related death and is a recalcitrant disease. We report here the efficacy and safety of intra-portal-vein (iPV) targeting of Salmonella typhimurium A1-R on colon cancer liver metastasis in a nude-mouse orthotopic model. Nude mice with HT29 human colon cancer cells, expressing red fluorescent protein (RFP) (HT29-RFP), growing in the liver were administered S. typhimurium A1-R by either iPV (1×104 colony forming units (CFU)/100 μl) or, for comparison, intra-venous injection (iv; 5×107 CFU/100 μl). Similar amounts of bacteria were delivered to the liver with the two doses, indicating that iPV delivery is 5×103 times more efficient than iv delivery. Treatment efficacy was evaluated by tumor fluorescent area (mm2) and total fluorescence intensity. Tumor fluorescent area and fluorescence intensity highly correlated (p<0.0001). iPV treatment was more effective compared to both untreated control and iv treatment (p<0.01 and p<0.05, respectively with iPV treatment with S. typhimurium arresting metastatic growth). There were no significant differences in body weight between all groups. The results of this study suggest that S. typhimurium A1-R administered iPV has potential for peri-operative adjuvant treatment of colon cancer liver metastasis.

Keywords: Salmonella typhimurium A1-R; liver metastasis; nude mice; orthotopic; tumor targeting.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Colonic Neoplasms / pathology*
  • HT29 Cells
  • Humans
  • Injections, Intravenous
  • Liver Neoplasms / secondary*
  • Mice
  • Mice, Nude
  • Portal Vein
  • Salmonella Infections, Animal*
  • Salmonella typhimurium*
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents